CONNECT Program Accelerates Precision Cancer Medicine in Norway

CONNECT Program Accelerates Precision Cancer Medicine in Norway

The Norwegian Precision Cancer Medicine Implementation Consortium, a landmark public-private initiative, represents a collaboration between 22 key public and private partners for promoting precision cancer medicine. Known as CONNECT, this newest initiative within the consortium represents one of four interconnected projects in this Scandinavian country that supports critical infrastructure and collaboration involving diagnostics, clinical trials, actual execution of advanced precision medicine and the use of health data for a range of important societal benefits such as for health economics analysis. Just recently, the multinational Japanese information technology and electronics company NEC joined the consortium embarking on a strategy to leverage mounting real-world data to reinforce and accelerate the firm’s personalized cancer immunotherapy efforts.

TrialSite introduces CONNECT and explores more about the implication for precision cancer care in Norway and beyond.

How many people are diagnosed with cancer in Norway annually?

30,000 and that number is growing.

What is precision cancer care?

According to the U.S. National Cancer Institute (NCI), precision med...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee